hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients

In this letter to the editor, the authors discuss the use of human equilibrative nucleoside transporter 1 (hENT-1) as a biomarker in patients with cholangiocarcinoma. They encourage standardization of techniques to evaluation expression of proteins such as hENT-1 and suggest additional studies inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Meijer, Laura L., Puik, Jisce R., Peters, Godefridus J., Kazemier, Geert, Giovannetti, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153344/
https://www.ncbi.nlm.nih.gov/pubmed/27807304
http://dx.doi.org/10.1634/theoncologist.2016-0262
_version_ 1782474674488213504
author Meijer, Laura L.
Puik, Jisce R.
Peters, Godefridus J.
Kazemier, Geert
Giovannetti, Elisa
author_facet Meijer, Laura L.
Puik, Jisce R.
Peters, Godefridus J.
Kazemier, Geert
Giovannetti, Elisa
author_sort Meijer, Laura L.
collection PubMed
description In this letter to the editor, the authors discuss the use of human equilibrative nucleoside transporter 1 (hENT-1) as a biomarker in patients with cholangiocarcinoma. They encourage standardization of techniques to evaluation expression of proteins such as hENT-1 and suggest additional studies investigating the active metabolites of gemcitabine, the use of liquid biopsies, and improved statistical methods.
format Online
Article
Text
id pubmed-5153344
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-51533442016-12-16 hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients Meijer, Laura L. Puik, Jisce R. Peters, Godefridus J. Kazemier, Geert Giovannetti, Elisa Oncologist Letters to the Editor In this letter to the editor, the authors discuss the use of human equilibrative nucleoside transporter 1 (hENT-1) as a biomarker in patients with cholangiocarcinoma. They encourage standardization of techniques to evaluation expression of proteins such as hENT-1 and suggest additional studies investigating the active metabolites of gemcitabine, the use of liquid biopsies, and improved statistical methods. AlphaMed Press 2016-12 2016-11-02 /pmc/articles/PMC5153344/ /pubmed/27807304 http://dx.doi.org/10.1634/theoncologist.2016-0262 Text en ©AlphaMed Press
spellingShingle Letters to the Editor
Meijer, Laura L.
Puik, Jisce R.
Peters, Godefridus J.
Kazemier, Geert
Giovannetti, Elisa
hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
title hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
title_full hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
title_fullStr hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
title_full_unstemmed hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
title_short hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
title_sort hent-1 expression and localization predict outcome after adjuvant gemcitabine in resected cholangiocarcinoma patients
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153344/
https://www.ncbi.nlm.nih.gov/pubmed/27807304
http://dx.doi.org/10.1634/theoncologist.2016-0262
work_keys_str_mv AT meijerlaural hent1expressionandlocalizationpredictoutcomeafteradjuvantgemcitabineinresectedcholangiocarcinomapatients
AT puikjiscer hent1expressionandlocalizationpredictoutcomeafteradjuvantgemcitabineinresectedcholangiocarcinomapatients
AT petersgodefridusj hent1expressionandlocalizationpredictoutcomeafteradjuvantgemcitabineinresectedcholangiocarcinomapatients
AT kazemiergeert hent1expressionandlocalizationpredictoutcomeafteradjuvantgemcitabineinresectedcholangiocarcinomapatients
AT giovannettielisa hent1expressionandlocalizationpredictoutcomeafteradjuvantgemcitabineinresectedcholangiocarcinomapatients

Ejemplares similares